New mode of treatment for lattice corneal dystrophy type I: corneal epithelial debridement and fibronectin eye drops

Morita, Yukiko; Chikama, T.–I.; Yamada, Naoyuki; Morishige, Naoyuki; Sonoda, Koh Hei; Nishida, Teruo

doi:10.1007/s10384-011-0104-5

Cited by 7 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, we have administered autologous fibronectin eyedrops to provide a provisional matrix after epithelial debridement in severe cases of ocular allergic disease, recurrent corneal erosion, and lattice corneal dystrophy (Fukuda et al, 2010;Morita et al, 2012). This is an adjunct use of fibronectin to achieve a rapid and complete epithelial resurfacing after the surgery.…”

Section: Autologous Fibronectin Eyedropsmentioning

confidence: 99%

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Nishida

Inui

Nomizu

2015

Progress in Retinal and Eye Research

Self Cite

View full text Add to dashboard Cite

The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision. The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth surface being essential for its optical properties. Disorders of the corneal epithelium include superficial punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of these disorders is important for minimization of further damage to the cornea. Currently available treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in order to allow natural healing to proceed. PEDs remain among the most difficult corneal conditions to treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular biological levels, we have strived to develop new modes of treatment for these defects. These treatments rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein fibronectin, for the attachment and migration of corneal epithelial cells, and activation of these cells by biological agents such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both approaches is the role of the fibronectin-integrin system in corneal epithelial wound healing. Determination of the minimum amino acid sequences required for the promotion of corneal epithelial wound closure by fibronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent molecules.

show abstract

Section: Autologous Fibronectin Eyedropsmentioning

confidence: 99%

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Nishida

Inui

Nomizu

2015

Progress in Retinal and Eye Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ocular surface disorders caused by infection, inflammation, and injury may cause a delay in wound healing of the corneal tissue such as the epithelium and stroma, ultimately resulting in visual disturbance and persistent pain. To activate the rapid regeneration of the corneal tissue, several growth factors such as epithelial growth factor (EGF), nerve growth factor (NGF), and fibroblast growth factor (FGF), as well as components of the extracellular matrix (ECM) such as fibronectin, are used as topical treatment [1][2][3][4]. However, because it may be difficult to extract and maintain these components and such process may be expensive, they are not widely used.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Preparation Methods for Platelet-Rich Plasma Eye Drops for Release of Growth Factors and De-Epithelization Rabbit Model

Kobayashi

Suzuki

Saito

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To compare two platelet-rich plasma (PRP) preparation methods (double spin (D-PRP) and TriCell PRP (T-PRP)) for eye drops, concentration yields of platelets and other cells, release of growth factors, and efficacy of the de-epithelization rabbit model. Methods. PRP was extracted by D-PRP and T-PRP from 30 ml blood from healthy adults. After extraction, platelets and leukocytes were counted. D-PRP and T-PRP were preserved during A: 1 h storage at room temperature, B: 1 h storage at −20°C, C: 24 h storage at 4°C, and D: 24 h storage at −20°C. Platelet-derived growth factor (PDGF) was measured. Freezing/thawing PRP eye drops and control were instilled in the de-epithelization rabbit model four times per day for 5 days. Histology was compared between eyes treated with control, D-PRP, and T-PRP. Results. 14 ml of D-PRP and 4 ml of T-PRP were extracted from 30 ml whole blood samples. D-PRP and T-PRP had 41.36 ± 8.43 × 104 and 67.02 ± 13.55 × 104 platelets and 0.41 ± 0.24 × 103/ml and 10.09 ± 4.29 × 103/ml leucocytes, respectively. In the four storage methods, PDGF concentrations in T-PRP were higher than those in D-PRP eye drops. Freezing/thawing D-PRP and T-PRP increased PDGF concentrations. Histology showed corneal epithelium thickness in T-PRP-treated eyes after healing (38.41 ± 9.10 μm) was significantly higher than that in control-treated (27.77 ± 4.76 μm) and D-PRP-treated eyes (18.32 ± 3.14 μm) ( P < 0.05). There was no corneal damage with inflammation in corneal stroma and epithelium of all tested groups. Electron microscopy revealed strong adhesion between cell junctions in T-PRP-treated eyes. Conclusions. Freezing/thawing of PRP extracted with the T-PRP kit may result in high platelet and leukocyte concentration and produce high PDGF concentration. PRP eye drops including leucocytes could increase thickness of corneal epithelium without corneal inflammation.

show abstract

Classic lattice corneal dystrophy: a brief review and summary of treatment modalities

Milovanova,

Gomon,

Rocha

2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

New mode of treatment for lattice corneal dystrophy type I: corneal epithelial debridement and fibronectin eye drops

Cited by 7 publications

References 18 publications

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Comparison of Two Preparation Methods for Platelet-Rich Plasma Eye Drops for Release of Growth Factors and De-Epithelization Rabbit Model

Classic lattice corneal dystrophy: a brief review and summary of treatment modalities

Contact Info

Product

Resources

About